A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma .

Trial Profile

A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma .

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms MAGNIFY
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 21 Jul 2017 Planned number of patients changed from 278 to 500.
    • 27 Jun 2017 Planned number of patients changed from 500 to 278.
    • 25 Jun 2017 Results evaluating safety and efficacy in patients with relapsed/refractory follicular lymphoma (n=106) presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top